On January 29, 2020 in the United States, Sorrento Therapeutics and Celularity jointly announced the start of clinical cooperation, with the purpose of extending Celularity’s CYNK – 001 (a allogeneic and placental origin natural killer cell therapy) to the treatment and prevention of coronavirus infection, in particular, novel coronaviruses (2019-ncov) emerging in 2019.
Natural Killer Cells (NK) are the basis of the innate immune response. The company’s research shows that placenta-derived NK cells are well tolerated, safe and versatile, and can be used in a wide range of organs and tissues. The potential of NK cell therapy for the treatment of various solid tumors is currently being investigated, and NK cell therapy has also demonstrated the potential of antiviral efficacy.
CYNK-001 is a cryopreservation allogeneic, readily available NK cell therapy that developed from placental hematopoietic stem cells and can be used as a potential treatment option for a variety of hematological neoplasms and solid tumors. NK cells are a unique class of immune cells with the innate ability to target cancer cells and interact with adaptive immunity. Placenta-derived NK cells are inherently safe and have a wide range of uses for a variety of organs and tissues.
Sorrento and Cellarity will evaluate CYNK-001 as a potential new therapy for the treatment and prevention of coronavirus, with particular attention to novel coronavirus emerging in 2019 (2019 nCoV).
Sorrento has been in touch with top Chinese scientists and local experts to discuss clinical collaborations and other related situations.